Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

In an effort to get more vulnerable people vaccinated against the virus the Government will allow hundreds of community ...

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A federal panel of medical experts on Wednesday recommended an expansion of respiratory syncytial virus (RSV) vaccinations ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

The pharmaceutical company said Thursday that the U.S. Advisory Committee on Immunization Practices had issued a positive recommendation on GSK's 5-in-1 meningitis vaccine Penmenvy as well as its ...